

Olivier Hermine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8413772/publications.pdf>

Version: 2024-02-01

239
papers

13,619
citations

26630

56
h-index

24982

109
g-index

245
all docs

245
docs citations

245
times ranked

15406
citing authors

#	ARTICLE	IF	CITATIONS
1	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2022, 36, 516-524.	7.2	29
2	Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. <i>Science Translational Medicine</i> , 2022, 14, eabj7521.	12.4	71
3	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 34-40.	0.9	26
4	Establishing diagnostic criteria for mastocytosis in skin biopsies. <i>Histopathology</i> , 2022, 80, 501-514.	2.9	9
5	UBA1 gene mutation in giant cell arteritis. <i>Clinical Rheumatology</i> , 2022, 41, 1257-1259.	2.2	6
6	Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1356-1364.e2.	3.8	2
7	Storage-Induced Micro-Erythrocytes Can Be Quantified and Sorted by Flow Cytometry. <i>Frontiers in Physiology</i> , 2022, 13, 838138.	2.8	1
8	Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	32
9	The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors. <i>Frontiers in Public Health</i> , 2022, 10, 816848.	2.7	6
10	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1999-2012.e6.	3.8	35
11	Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry. <i>HemaSphere</i> , 2022, 6, e0711.	2.7	7
12	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1855-1865.	2.9	19
13	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	7.1	110
14	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 2482-2494.	27.0	83
15	KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target. <i>Blood</i> , 2022, 140, 1522-1532.	1.4	5
16	Improving the diagnostic efficiency of primary immunodeficiencies with targeted next-generation sequencing. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 734-737.	2.9	17
17	Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2021, 56, 605-613.	2.4	6
18	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 32.	5.1	654

#	ARTICLE	IF	CITATIONS
19	Criteria for the Regression of Pediatric Mastocytosis: A Long-Term Follow-Up. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1695-1704.e5.	3.8	10
20	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021, 11, 292-303.	10.0	26
21	Loss of interleukin-10 activates innate immunity to eradicate adult T-cell leukemia-initiating cells. <i>Haematologica</i> , 2021, 106, 1443-1456.	3.5	11
22	Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T cell leukemia. <i>Haematologica</i> , 2021, 106, 2076-2085.	3.5	12
23	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 295-304.	10.7	232
24	Substitution of opioids by N-methyl-D-aspartate receptor antagonists for treating pain in mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 293-295.	1.0	2
25	Rapid clearance of storage-induced microerythrocytes alters transfusion recovery. <i>Blood</i> , 2021, 137, 2285-2298.	1.4	45
26	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1705-1712.e4.	3.8	13
27	Tocilizumab in Treatment for Patients With COVID-19â€”Reply. <i>JAMA Internal Medicine</i> , 2021, 181, 1020-1021.	5.1	1
28	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	185
29	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/Cell lymphoma, nasal type: A French study from the SociÃ©tÃ© Francophone de Greffe de Moelle et de ThÃ©rapie Cellulaire (SFGMâ€”TC). <i>American Journal of Hematology</i> , 2021, 96, 834-845.	4.1	5
30	GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness. <i>Blood</i> , 2021, 138, 1590-1602.	1.4	4
31	Atypical splice-site mutations causing VEXAS syndrome. <i>Rheumatology</i> , 2021, 60, e435-e437.	1.9	40
32	Biallelic mutations in the <i>SARS2</i> gene presenting as congenital sideroblastic anemia. <i>Haematologica</i> , 2021, 106, 3202-3205.	3.5	2
33	Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa. <i>Annals of Hematology</i> , 2021, 100, 2813-2824.	1.8	11
34	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	7.4	498
35	The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis. <i>Blood</i> , 2021, 138, 2396-2407.	1.4	5
36	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	11.9	357

#	ARTICLE	IF	CITATIONS
37	Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1241.	5.1	111
38	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021, 13, 4503.	3.7	7
39	Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110303.	3.5	28
40	Metabolic rejuvenation upgrades circulatory functions of red blood cells stored under blood bank conditions. <i>Transfusion</i> , 2021, 61, 903-918.	1.6	11
41	Urea-Peptide Hybrids as VEGF-A165/NRP-1 Complex Inhibitors with Improved Receptor Affinity and Biological Properties. <i>International Journal of Molecular Sciences</i> , 2021, 22, 72.	4.1	8
42	Clinical, laboratory and ultrasonographic findings differentiating low-grade intestinal T-cell lymphoma from lymphoplasmacytic enteritis in cats. <i>Journal of Veterinary Internal Medicine</i> , 2021, . .	1.6	8
43	Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities. <i>Current Oncology Reports</i> , 2021, 23, 141.	4.0	13
44	A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa. <i>Blood</i> , 2021, 138, 3495-3495.	1.4	0
45	The EHA Research Roadmap: Normal Hematopoiesis. <i>HemaSphere</i> , 2021, 5, e669.	2.7	1
46	Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network. <i>Blood</i> , 2021, 138, 380-380.	1.4	10
47	Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. <i>Nature Medicine</i> , 2021, 27, 2192-2199.	30.7	79
48	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. <i>Frontiers in Veterinary Science</i> , 2021, 8, 755258.	2.2	16
49	Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 5-14.	1.7	133
50	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020, 34, 1090-1101.	7.2	34
51	Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. <i>Journal of Infection</i> , 2020, 80, 219-224.	3.3	8
52	Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Leukemia</i> , 2020, 34, 1462-1466.	7.2	30
53	Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 2170-2179.	2.4	8
54	Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies. <i>Haematologica</i> , 2020, 105, e461-464.	3.5	7

#	ARTICLE	IF	CITATIONS
55	Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma. <i>Frontiers in Microbiology</i> , 2020, 11, 1207.	3.5	34
56	Novel Treatments of Adult T Cell Leukemia Lymphoma. <i>Frontiers in Microbiology</i> , 2020, 11, 1062.	3.5	31
57	Does Cysteine Rule (CysR) Complete the CendR Principle? Increase in Affinity of Peptide Ligands for NRP-1 Through the Presence of N-Terminal Cysteine. <i>Biomolecules</i> , 2020, 10, 448.	4.0	7
58	Arsenic trioxide (As ₂ O ₃) as a maintenance therapy for adult T cell leukemia/lymphoma. <i>Retrovirology</i> , 2020, 17, 5.	2.0	20
59	Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA. <i>Annals of Hematology</i> , 2020, 99, 1771-1778.	1.8	8
60	Effects of Chronic Masitinib Treatment in APP ^{swe} /PSEN1 ^{dE9} Transgenic Mice Modeling Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1339-1345.	2.6	26
61	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 356-366.e4.	2.9	42
62	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	5.7	47
63	Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. <i>Cell Reports</i> , 2020, 30, 739-754.e4.	6.4	32
64	A toxic palmitoylation of Cdc42 enhances NF- κ B signaling and drives a severe autoinflammatory syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1201-1204.e8.	2.9	33
65	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. <i>Blood</i> , 2020, 136, 8-9.	1.4	7
66	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β -Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. <i>Blood</i> , 2020, 136, 45-46.	1.4	8
67	Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial. <i>Blood</i> , 2020, 136, 42-42.	1.4	0
68	Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups. <i>Blood</i> , 2020, 136, 20-21.	1.4	3
69	Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2020, 136, 12-13.	1.4	8
70	Congenital Neutropenia Is Also Associated with a High Cancer Risk: A Study from the French Severe Chronic Neutropenia Registry. <i>Blood</i> , 2020, 136, 15-16.	1.4	15
71	Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 1-10.	1.8	18
72	Validation of the <sc>MCL</sc>35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. <i>British Journal of Haematology</i> , 2019, 184, 616-624.	2.5	25

#	ARTICLE	IF	CITATIONS
73	Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock. <i>Allergy International</i> , 2019, 68, 119-121.	3.3	2
74	Neuroinflammatory disorders and mastocytosis: A possible association?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2878-2881.e1.	3.8	2
75	Urea moiety as amide bond mimetic in peptide-like inhibitors of VEGF-A165/NRP-1 complex. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2493-2497.	2.2	7
76	Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2387-2395.e3.	3.8	42
77	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. <i>Leukemia</i> , 2019, 33, 1687-1699.	7.2	98
78	Neuropilin-1 peptide-like ligands with proline mimetics, tested using the improved chemiluminescence affinity detection method. <i>MedChemComm</i> , 2019, 10, 332-340.	3.4	12
79	Neurological Involvement in Childhood Evans Syndrome. <i>Journal of Clinical Immunology</i> , 2019, 39, 171-181.	3.8	6
80	Regulation of globin-heme balance in Diamond-Blackfan anemia by HSP70/GATA1. <i>Blood</i> , 2019, 133, 1358-1370.	1.4	44
81	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. <i>Journal of Clinical Oncology</i> , 2019, 37, 677-687.	1.6	162
82	Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin. <i>Cell Reports</i> , 2019, 26, 3246-3256.e4.	6.4	15
83	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1125-1133.e1.	3.8	150
84	Inflammatory disorders associated with trisomy 8 in myelodysplastic syndromes: French retrospective case-control study. <i>European Journal of Haematology</i> , 2019, 102, 63-69.	2.2	20
85	NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. <i>Gut</i> , 2019, 68, 1396-1405.	12.1	47
86	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	3.8	42
87	Gastrointestinal Behçet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1782-1788.	1.3	22
88	High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies. <i>Supportive Care in Cancer</i> , 2019, 27, 3053-3059.	2.2	18
89	A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 111-122.	2.8	12
90	Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS). <i>British Journal of Haematology</i> , 2019, 184, 472-475.	2.5	12

#	ARTICLE	IF	CITATIONS
91	Storage-Induced Micro-Erythrocytes Are Rapidly Cleared from Recipient Circulation and Predict Transfusion Recovery. <i>Blood</i> , 2019, 134, 717-717.	1.4	5
92	Recent advances in the understanding and therapeutic management of mastocytosis. <i>F1000Research</i> , 2019, 8, 1961.	1.6	12
93	Serotonin Targeting Using Common Antidepressants Induces Rapid Recovery of Cytopenia. <i>Blood</i> , 2019, 134, 3715-3715.	1.4	0
94	French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up. <i>Blood</i> , 2019, 134, 1537-1537.	1.4	0
95	A Review of New Findings in Adult T-cell Leukemia/Lymphoma: A Focus on Current and Emerging Treatment Strategies. <i>Advances in Therapy</i> , 2018, 35, 135-152.	2.9	72
96	Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. <i>Blood</i> , 2018, 131, 417-420.	1.4	108
97	Feline low-grade alimentary lymphoma: an emerging entity and a potential animal model for human disease. <i>BMC Veterinary Research</i> , 2018, 14, 306.	1.9	53
98	Fluorescence Exclusion: A Simple Method to Assess Projected Surface, Volume and Morphology of Red Blood Cells Stored in Blood Bank. <i>Frontiers in Medicine</i> , 2018, 5, 164.	2.6	12
99	Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma. <i>Frontiers in Microbiology</i> , 2018, 9, 925.	3.5	10
100	Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases. <i>Clinical Immunology</i> , 2018, 194, 75-79.	3.2	10
101	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. <i>Blood</i> , 2018, 132, 163-163.	1.4	11
102	Omalizumab: Efficacy and Safety in Mast Cell Disorders. <i>Blood</i> , 2018, 132, 4280-4280.	1.4	0
103	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2017, 389, 612-620.	13.7	95
104	Spherocytic shift of red blood cells during storage provides a quantitative whole cell-based marker of the storage lesion. <i>Transfusion</i> , 2017, 57, 1007-1018.	1.6	62
105	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 1223-1230.	1.6	37
106	Hepatitis C virus Associated marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 41-49.	1.7	16
107	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.9	210
108	Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma. <i>Methods in Molecular Biology</i> , 2017, 1582, 197-216.	0.9	23

#	ARTICLE	IF	CITATIONS
109	Prevalence and risk factors for fragility fracture in systemic mastocytosis. <i>Bone</i> , 2017, 105, 219-225.	2.9	28
110	Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 864-868.	1.7	33
111	Physical health conditions and quality of life in adults with primary immunodeficiency diagnosed during childhood: A French Reference Center for PIDs (CEREDIH) study. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1275-1281.e7.	2.9	26
112	Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon- α . <i>Blood Advances</i> , 2017, 1, 748-752.	5.2	23
113	ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 68.	3.4	332
114	Targeted Treatment Options in Mastocytosis. <i>Frontiers in Medicine</i> , 2017, 4, 110.	2.6	22
115	The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70. <i>Blood Advances</i> , 2017, 1, 1959-1976.	5.2	34
116	Adult T cell leukemia aggressiveness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. <i>Oncotarget</i> , 2017, 8, 52256-52268.	1.8	20
117	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , 2016, 128, 2527-2532.	1.4	149
118	Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. <i>Haematologica</i> , 2016, 101, 336-345.	3.5	50
119	Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). <i>Lancet Infectious Diseases</i> , The, 2016, 16, 606-617.	9.1	118
120	Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 416-424.	2.3	19
121	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016, 101, 1133-1143.	3.5	60
122	Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2016, 13, 177.	7.2	116
123	Clonal eosinophil and mast cell diseases: different in the same way?. <i>Expert Review of Hematology</i> , 2016, 9, 1107-1109.	2.2	3
124	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	13.7	328
125	Early High-Dose Erythropoietin Therapy After Out-of-Hospital Cardiac Arrest. <i>Journal of the American College of Cardiology</i> , 2016, 68, 40-49.	2.8	43
126	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016, 374, 2530-2541.	27.0	383

#	ARTICLE	IF	CITATIONS
127	Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. <i>Cancer Discovery</i> , 2016, 6, 972-985.	9.4	33
128	Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 885-891.e1.	1.2	30
129	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> . 2016. 137, 35-45.	2.9	289
130	TCL1 expression patterns in Waldenström macroglobulinemia. <i>Modern Pathology</i> , 2016, 29, 83-88.	5.5	4
131	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1213-1224.	6.1	44
132	Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. <i>Blood</i> , 2016, 128, 145-145.	1.4	38
133	Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T3 Phase IB Trial of the Lysa Group. <i>Blood</i> , 2016, 128, 2987-2987.	1.4	1
134	BID Cleavage Pattern Is a Novel Check-Point That Determines the Fate of Human Erythroid Progenitors		

#	ARTICLE	IF	CITATIONS
145	Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. <i>European Journal of Haematology</i> , 2015, 94, 474-490.	2.2	64
146	Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene. <i>Biochimie</i> , 2015, 119, 1-5.	2.6	28
147	A neuropathological study of cerebrovascular abnormalities in a signal transducer and activator of transcription 3-deficient patient. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1418-1421.e5.	2.9	5
148	Incidence, Presentation, and Prognosis of Malignancies in Ataxia-Telangiectasia: A Report From the French National Registry of Primary Immune Deficiencies. <i>Journal of Clinical Oncology</i> , 2015, 33, 202-208.	1.6	176
149	Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector. <i>Blood</i> , 2015, 126, 202-202.	1.4	28
150	XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia. <i>Blood</i> , 2015, 126, 2368-2368.	1.4	4
151	Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2015, 126, 335-335.	1.4	6
152	Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2015, 126, 338-338.	1.4	19
153	Anti-Lymphoma Activity of Interferon-Free Antiviral Treatment in Patients with Indolent B-Cell Lymphomas Associated with Hepatitis C Virus Infection. <i>Blood</i> , 2015, 126, 3938-3938.	1.4	5
154	Masitinib plus FOLFIRI for second line treatment of metastatic colorectal cancer: An open label phase Ib/II trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3526-3526.	1.6	4
155	Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 4027-4027.	1.6	1
156	Masitinib plus carboplatin and gemcitabine for treatment of patients with advanced triple negative breast cancer: An open label phase Ib/II trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1070-1070.	1.6	0
157	HSP70, the Key to Account for Erythroid Tropism of Diamond-Blackfan Anemia?. <i>Blood</i> , 2015, 126, 671-671.	1.4	0
158	Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3993-3993.	1.4	0
159	Semaphorin 3F and Neuropilin-2 Control the Migration of Human T-Cell Precursors. <i>PLoS ONE</i> , 2014, 9, e103405.	2.5	40
160	Association of mastocytosis with inflammatory joint diseases: A series of 31 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 362-365.	3.4	12
161	Molecular Defects in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 239-262.	1.9	67
162	Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 944, 175-181.	2.3	13

#	ARTICLE	IF	CITATIONS
163	HSP70 sequestration by free β_2 -globin promotes ineffective erythropoiesis in β_2 -thalassaemia. <i>Nature</i> , 2014, 514, 242-246.	27.8	124
164	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	1.6	146
165	Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model. <i>Cancer Letters</i> , 2014, 349, 120-127.	7.2	46
166	SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. <i>Haematologica</i> , 2014, 99, 830-835.	3.5	55
167	MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network. <i>Blood</i> , 2014, 124, 147-147.	1.4	13
168	Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma " Results from Randomized Trials of the European MCL Network. <i>Blood</i> , 2014, 124, 2977-2977.	1.4	4
169	Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8622-TPS8622.	1.6	0
170	Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study. <i>Blood</i> , 2014, 124, 1657-1657.	1.4	0
171	Lymphoproliferative Disease in Wiskott-Aldrich Syndrome: Analysis of the French National Registry of Primary Immunodeficiencies. <i>Blood</i> , 2014, 124, 4129-4129.	1.4	0
172	Mast cell leukemia. <i>Blood</i> , 2013, 121, 1285-1295.	1.4	153
173	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	1.4	122
174	Ineffective Erythropoiesis in β_2 -Thalassemia. <i>Scientific World Journal</i> , The, 2013, 2013, 1-11.	2.1	92
175	The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients. <i>Blood</i> , 2013, 122, 2193-2193.	1.4	2
176	Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 158-158.	1.6	5
177	A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8613-TPS8613.	1.6	2
178	Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. <i>Blood</i> , 2013, 122, 2202-2202.	1.4	0
179	Outcome Of Patients With HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma (ATL) Who Have Undergone Stem Cell Transplantation: A Retrospective Study Of The EBMT Lymphoma Working Party. <i>Blood</i> , 2013, 122, 3398-3398.	1.4	0
180	Phenotypic and Functional Characterization Of a Novel Immature Hematopoietic Myeloid Suppressive Progenitor Cells Mobilized By G-CSF. Application To Gvhd Treatment. <i>Blood</i> , 2013, 122, 4476-4476.	1.4	0

#	ARTICLE	IF	CITATIONS
181	The Combination Of Arsenic, Interferon-Alpha, and Zidovudine Restores An "Immunocompetent-like" Micro-Environment In Patients With Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2013, 122, 5100-5100.	1.4	0
182	Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. <i>Blood</i> , 2013, 122, 3663-3663.	1.4	0
183	In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. <i>Blood</i> , 2012, 120, 4846-4849.	1.4	89
184	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 807-814.	1.9	33
185	Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. <i>BMC Neurology</i> , 2012, 12, 36.	1.8	104
186	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). <i>Blood</i> , 2012, 120, 151-151.	1.4	52
187	Modulation of Activin Signaling by RAP-011 (ActRIIA-IgG1) Improve Anemia, Increases Hemoglobin Levels and Corrects Ineffective Erythropoiesis in β^2 -Thalassemia. <i>Blood</i> , 2012, 120, 247-247.	1.4	1
188	Masitinib mesylate in imatinib-resistant advanced GIST: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10007-10007.	1.6	3
189	Masitinib in imatinib-naive advanced gastrointestinal stromal tumor (GIST): Five-year follow-up of the French Sarcoma Group phase II trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10089-10089.	1.6	2
190	Masitinib in comparison to imatinib as first-line therapy of patients with advanced gastrointestinal stromal tumor (GIST): A randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS10102-TPS10102.	1.6	0
191	Heat Shock Protein 70 Cytosolic Sequestration by Excess of Free Alpha-Globin Chains Is a Key Mechanism of the Ineffective Erythropoiesis in β^2 -Thalassemia Major Patients. <i>Blood</i> , 2012, 120, 823-823.	1.4	0
192	Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Assay for the Simultaneous Quantification of Midostaurin (PKC412) and Its Two Major Metabolites: A Suitable Tool for the Monitoring of the Drug in Patients Suffering From Advanced Systemic Mastocytosis. <i>Blood</i> , 2012, 120, 4913-4913.	1.4	3
193	High Level of CD71 Expression On Neoplastic B Cells At Diagnosis Is Predictive of Overall Survival After Rituximab and Anthracyclines Based Regimen in Follicular Lymphoma. <i>Blood</i> , 2012, 120, 1601-1601.	1.4	8
194	Occurrence of Malignancies in Patients with Primary Immunodeficiencies: An Analysis of the French Primary Immunodeficiency Registry. <i>Blood</i> , 2012, 120, 1057-1057.	1.4	0
195	Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 16.	6.2	128
196	How I treat adult T-cell leukemia/lymphoma. <i>Blood</i> , 2011, 118, 1736-1745.	1.4	143
197	Controversies in Targeted Therapy of Adult T Cell Leukemia/Lymphoma: ON Target or OFF Target Effects?. <i>Viruses</i> , 2011, 3, 750-769.	3.3	35
198	Polymeric Immunoglobulin A1 Controls Erythroblast Proliferation and Accelerates Erythropoiesis Recovery in Anemia. <i>Blood</i> , 2011, 118, 679-679.	1.4	4

#	ARTICLE	IF	CITATIONS
199	Thalidomide in Advanced Mastocytosis. Results from an Open-Label, Multicentric, Phase II Study. <i>Blood</i> , 2011, 118, 1754-1754.	1.4	3
200	Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T-Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes. <i>Journal of Clinical Oncology</i> , 2010, 28, 4177-4183.	1.6	323
201	Reply to K. Ishitsuka et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e766-e766.	1.6	0
202	Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. <i>Journal of Experimental Medicine</i> , 2010, 207, 2785-2792.	8.5	85
203	Pediatric Mastocytosis Is a Clonal Disease Associated with D816V and Other Activating c-KIT Mutations. <i>Journal of Investigative Dermatology</i> , 2010, 130, 804-815.	0.7	329
204	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	27
205	High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial. <i>Blood</i> , 2010, 116, 1758-1758.	1.4	2
206	Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program.. <i>Blood</i> , 2010, 116, 1794-1794.	1.4	3
207	Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients. <i>Blood</i> , 2010, 116, 1982-1982.	1.4	12
208	Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma?: a Retrospective Study From the Lymphoma Working Party of the EBMT. <i>Blood</i> , 2010, 116, 688-688.	1.4	14
209	R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network. <i>Blood</i> , 2010, 116, 965-965.	1.4	18
210	Association of Langerhans Cell Histiocytosis with Erdheim-Chester Disease: How Close Monocyte/Macrophage and Dendritic Cell Lineages Are?. <i>Blood</i> , 2010, 116, 4716-4716.	1.4	0
211	Favourable Outcome of B-Cell Non Hodgkin Lymphomas Associated with Hepatitis C Virus - ANRS HC13 LYMPHO-C Observational Study. <i>Blood</i> , 2010, 116, 3116-3116.	1.4	0
212	Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2009, 27, 453-459.	1.6	485
213	Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT. <i>PLoS ONE</i> , 2009, 4, e7258.	2.5	346
214	Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). <i>Blood</i> , 2009, 113, 6528-6532.	1.4	175
215	Eight Colors Flow Cytometry Phenotyping for Blood Minimal Residual Disease Monitoring in Hairy Cell Leukaemia Patients.. <i>Blood</i> , 2009, 114, 1609-1609.	1.4	1
216	The Type of Enteropathy Is a Prognostic Factor in Enteropathy-Associated T-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 2937-2937.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Prognostic Significance of Complement System Activation After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 1166-1166.	1.4	4
218	Impact of Donor-Derived Invariant Natural Killer T (iNKT) Cell Reconstitution After Allogeneic Haematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 346-346.	1.4	30
219	Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors. Molecular Cancer Research, 2008, 6, 1137-1145.	3.4	147
220	Prospective Multicenter Study for Evaluating Cognitive Disorders in Hematology-Oncology: A Pilot Study of 118 Patients. Blood, 2008, 112, 1309-1309.	1.4	0
221	Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature, 2007, 445, 102-105.	27.8	246
222	A Worldwide Meta-Analysis on the Use of Zidovudine and Interferon-alpha for the Treatment of Adult Tâ€Cell Leukemia/Lymphoma.. Blood, 2007, 110, 2049-2049.	1.4	12
223	FGFR3 Tyrosine Kinase Inhibitor AB1010 as Treatment of t(4;14) Multiple Myeloma.. Blood, 2007, 110, 413-413.	1.4	5
224	Molecular Mechanisms of NF-kappaB Activation by the HTLV-I Oncoprotein Tax: Role of Post Translational Protein Modification.. Blood, 2007, 110, 4159-4159.	1.4	0
225	Targeted Therapy with Arsenic Trioxide and Interferon alpha Eradicates Leukemic Cells in SCID Mice Model of Adult T-Cell Leukemia/Lymphoma.. Blood, 2007, 110, 1379-1379.	1.4	4
226	Complement System Activation after Allogeneic Bone Marrow Transplantation May Early Predict the Development of Acute Gastrointestinal GVHD.. Blood, 2007, 110, 2186-2186.	1.4	0
227	Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood, 2006, 108, 1065-1072.	1.4	62
228	JNK Pathway Is Constitutively Activated and Is Required for Survival in Human Mantle-Cell Lymphoma Fresh Cells and Cell-Lines.. Blood, 2006, 108, 4602-4602.	1.4	0
229	Tax Ubiquitylation and Sumoylation Control the Two Distinct Steps of NF-Î²B Activation.. Blood, 2005, 106, 4353-4353.	1.4	0
230	Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. The Hematology Journal, 2004, 5, 130-134.	1.4	128
231	L-Asparaginase in the Treatment of Relapsing Nasal/Nasal Type NK-T-Cell Lymphoma.. Blood, 2004, 104, 4598-4598.	1.4	0
232	Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection. New England Journal of Medicine, 2002, 347, 89-94.	27.0	760
233	A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. The Hematology Journal, 2002, 3, 276-282.	1.4	108
234	Caspase Activation Is Required for Terminal Erythroid Differentiation. Journal of Experimental Medicine, 2001, 193, 247-254.	8.5	387

#	ARTICLE	IF	CITATIONS
235	Arsenic Trioxide and Interferon- α Synergize to Induce Cell Cycle Arrest and Apoptosis in Human T-Cell Lymphotropic Virus Type β -Transformed Cells. <i>Blood</i> , 1999, 93, 278-283.	1.4	174
236	Comparison of Lenograstim vs Filgrastim Administration following Chemotherapy for Peripheral Blood Stem Cell (PBSC) Collection: A Retrospective Study of 126 Patients. <i>Leukemia and Lymphoma</i> , 1999, 35, 501-505.	1.3	30
237	Adult T Cell Leukaemia. <i>BioDrugs</i> , 1998, 10, 447-462.	4.6	38
238	Treatment with a Combination of Zidovudine and β -Interferon in Naive and Pretreated Adult T-Cell Leukemia/Lymphoma Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, S186-S190.	0.3	60
239	Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa. <i>New England Journal of Medicine</i> , 1995, 332, 1749-1751.	27.0	261